glp-1 drug market size Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Receptor Agonist Market Size,

The case for incretin therapy was once again dismissed in 1950 by Morton Grossman, one of Ivys former students

Initial research is highly concerning that these medications have side effects that need further research before widespread drug administration and adoption, significantly decrease muscle mass, and can cause significant weight gain after stopping

While these medications don't directly damage eye structures, clinical evidence shows they may worsen diabetic retinopathy in specific circumstancesparticularly when patients with pre-existing retinal disease experience rapid blood sugar improvements

doi: 10.1016/j.cbi.2018.01.004

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

GLP-1 receptor agonists augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying while inhibiting food intake and reducing body weight